Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that ...
Tech That Scales: A Practical Framework for Artificial Intelligence–Enabled Cancer Care in Low- and Middle-Income Countries and Underserved US Counties Desmoid tumors (DTs) are rare fibroblastic ...
Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls. Brooke’s mother also had 28 surgeries related to her desmoid tumors and multiple ...
SpringWorks Therapeutics announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nirogacestat, an oral gamma secretase inhibitor, ...
FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...
Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, ...
STAMFORD, Conn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today ...
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Latest ...
Liposomal vs conventional doxorubicin as first-line therapy in advanced soft tissue sarcomas: A tertiary US center’s 8.5-year experience. Clinical outcomes of Kaposi's sarcoma in a cohort of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results